Cronies Pharma & Bio-Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 9.60 M
as on 16-11-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.20 Cr
as on 16-11-2024
- Satisfied Charges ₹ 1.89 Cr
as on 16-11-2024
- Revenue 39.59%
(FY 2023)
- Profit 22.87%
(FY 2023)
- Ebitda 43.92%
(FY 2023)
- Net Worth 45.00%
(FY 2023)
- Total Assets 33.52%
(FY 2023)
About Cronies Pharma & Bio-Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.60 M.
The company currently has active open charges totaling ₹2.20 Cr. The company has closed loans amounting to ₹1.89 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kirankumar Velaveni and Kalpana Ravanaboina serve as directors at the Company.
- CIN/LLPIN
U74999TG2016PTC109657
- Company No.
109657
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 May 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cronies Pharma & Bio-Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kirankumar Velaveni  | Director | 14-May-2016 | Current |
| Kalpana Ravanaboina | Director | 14-May-2016 | Current |
Financial Performance of Cronies Pharma & Bio-Sciences.
Cronies Pharma & Bio-Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 39.59% increase. The company also saw a substantial improvement in profitability, with a 22.87% increase in profit. The company's net worth Soared by an impressive increase of 45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cronies Pharma & Bio-Sciences?
In 2023, Cronies Pharma & Bio-Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Velzen Pharma Private LimitedActive 2 years 8 months
Kirankumar Velaveni and Kalpana Ravanaboina are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Feb 2023 | ₹2.20 Cr | Open |
State Bank Of India Creation Date: 27 Dec 2019 | ₹1.89 Cr | Satisfied |
How Many Employees Work at Cronies Pharma & Bio-Sciences?
Unlock and access historical data on people associated with Cronies Pharma & Bio-Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cronies Pharma & Bio-Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cronies Pharma & Bio-Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
